Evaluation of the changes in choroidal macular anastomoses after photodynamic therapy and in the follow-up of central serous chorioretinopathy by en face optical coherence tomography

Photodiagnosis Photodyn Ther. 2023 Sep:43:103719. doi: 10.1016/j.pdpdt.2023.103719. Epub 2023 Jul 22.

Abstract

Purpose: To evaluate the changes in the choroidal macular anastomoses after photodynamic therapy (PDT) and in the follow-up of patients with central serous chorioretinopathy (CSCR) by en face optical coherence tomography (EF-OCT).

Methods: Prospective study using EF-OCT images of patients with chronic CSCR treated by PDT with a minimum follow-up of 12 months and with the presence of at least two prominent anastomoses in the macula. Scans of 6 × 6 mm and 12 × 12 mm were made to assess the changes in choroidal macular anastomoses (defined as a diameter ≥150 µm) crossing the medial raphe. EF-OCT was performed before PDT and 3 days, 3 months and at the end of the follow-up after PDT.

Results: The mean follow-up time was 23.6 ± 12.1 months. The mean number of anastomoses was 2.5 ± 1.1 in the baseline examination, being 2.3 ± 1.2 in the final examination, with no differences being observed (p = 0.110). A sub-analysis was performed to assess differences in the evolution of the anastomoses between active chronic CSCR and those in which the subretinal fluid (SRF) had been resolved, with no differences being observed in the number or caliber of anastomoses (p = 0.642 and p = 0.306). A significant decrease in the size of anastomoses was found at the 3-day (p<0.01) and 3-month (p = 0.032) visits, but not at the last follow-up visit (p = 0.156).

Conclusions: There was an early decrease in the size of the major macular choroidal anastomotic vessels after PDT treatment. Long-term studies are required to assess its evolution and its possible role in the etiopathogenesis of this disease.

Keywords: Central serous chorioretinopathy; Choroid; En face optical coherence tomography; Macular anastomosis; OCT; Pachychoroid disease.

MeSH terms

  • Central Serous Chorioretinopathy* / drug therapy
  • Chronic Disease
  • Fluorescein Angiography / methods
  • Follow-Up Studies
  • Humans
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Prospective Studies
  • Retrospective Studies
  • Tomography, Optical Coherence / methods
  • Verteporfin / therapeutic use
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Verteporfin